Abstract
Inflammation is the body’s defense mechanism against external stressors. However, diseases including rheumatoid arthritis, cancer, diabetes, allergies, and infections have all been linked to excessive physiopathological damage. Anti-inflammatory drugs are used to treat inflammation symptoms, which mostly include pain, an increase in body temperature, flushing, and edema. It has been determined in this case to focus on prostaglandin E2 (PGE2) inhibition while developing novel anti-inflammatory medications. The treatment of inflammatory illnesses with the least amount of adverse effects possible could be achieved by selectively inhibiting both cyclooxygenase (COX) and lipoxygenase (LOX). Recently, approaches for computer-aided drug design (CADD) have been employed with effectiveness in the procedures of developing medications. This article presents a thorough analysis of structure-based drug design proposals for the creation of novel LOX inhibitors and COX inhibitors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
